The cholinergic system plays an important role in regulation of arousal and REM sleep. In the present study, we showed that a muscarinic receptor agonist, carbachol (CCh), activates almost 20% of orexin-producing neurons (orexin neurons), which play a critical role in maintenance of arousal. We also found that a very small population of orexin neurons (1%) was inhibited by CCh. Muscarinic receptor antagonists inhibited the CCh-induced activation of orexin neurons in a dose-dependent manner. The M 3 -selective muscarinic receptor antagonist 4diphenylacetoxy-N-methyl-piperidine methiodide (4-DAMP) affected the response at a significantly lower concentration compared with the M 1 -selective muscarinic antagonist pirenzepine. IC 50 of 4-DAMP and pirenzepine was 0.30 ± 0.15 and 59.9 ± 18.6 nM, respectively. The CChinduced inward current was attenuated by the nonselective cation channel blocker SKF96365. These results indicate that CCh activates 20% of orexin neurons through the M 3 muscarinic receptor and subsequent activation of nonselective cation channels.
Introduction
Orexin A and orexin B, also called hypocretin-1 and hypocretin-2, are a pair of hypothalamic neuropeptides implicated in regulation of sleep / wake states (1) . Orexin neurons are localized exclusively in the lateral hypothalamic area (LHA), but they project to almost all regions of the brain except the cerebellum. Especially, dense projections of orexin neurons are observed in the monoaminergic and cholinergic nuclei located in the midbrain and hypothalamus, including the serotonergic dorsal raphe nuclei (DR), noradrenergic locus coeruleus (LC), histaminergic tuberomammillary nucleus (TMN), and cholinergic laterodorsal tegmental/ pedunculopontine nucleus (LDT / PPN) (2 -4) .
The orexin system plays a crucial role in sleep / wakefulness regulation. Orexin deficiency in humans causes a sleep disorder, narcolepsy (5, 6) . Prepro-orexin knockout mice and orexin /ataxin-3 mice (which lack orexin neurons) exhibit a phenotype remarkably similar to human narcolepsy, including cataplexy-like attacks and fragmented sleep / wake states (7, 8) . Reciprocal links between orexin neurons and monoaminergic neurons/ cholinergic neurons are thought to be important for proper regulation of sleep / wake states (9, 10) .
Cholinergic neurons in the central nervous system in the basal forebrain (BF), including the basal nucleus of Mynert, medial septal nucleus, vertical and horizontal limb of the diagonal band nucleus and magnocellular preoptic nucleus, and the midbrain, including the LDT / PPN, are thought to play an important role in regulation of vigilance states. The activity of these cholinergic neurons depends on the vigilance state. There are two classes of cholinergic neurons regarding the activity during each state; one is active during both the awake and REM sleep periods, and the other is active only in the REM sleep period (11, 12) . These observations suggest that interaction between orexin neurons and the cholinergic system might be important for regulation of sleep / wake states. Orexin neurons innervate and activate cholinergic neurons in the BF and LDT / PPN (13 -15) . Our previous study showed that acetylcholine activates or inhibits some populations of orexin neurons in mice (16, 17) . However, Li et al. reported that acetylcholine had little effect on orexin neurons in mice (18) . This discrepancy might stem from the number of neurons examined in these studies because only a small population of orexin neurons is influenced by cholinergic agonists (16) .
In the present study, we applied the patch clamp method to a large number (more than 200) of orexin neurons to determine the extent to which orexin neurons are influenced by cholinergic agonists and examined the intracellular mechanisms by which acetylcholine affects orexin neurons. We found that a cholinergic agonist, carbachol (CCh), induced inward current in almost 20% of orexin neurons by activation of nonselective cation channels (NSCC) through the M 3 muscarinic receptors.
Materials and Methods

Animals
All experimental procedures involving animals were approved by the University of Tsukuba Animal Resource Center and were in accordance with NIH guidelines. All efforts were made to minimize animal suffering and to reduce the number of animals used.
Slice preparation and electrophysiological recording
Slices for electrophysiological study were prepared from orexin/EGFP mice as previously described (16, 17, 19 -22) . Electrophysiological recordings were carried out with an Axopatch 200B amplifier (Axon Instruments, Foster City, CA, USA) using a borosilicate pipette filled with intracellular solution containing 140 mM KCl, 0.1 mM MgCl 2 , 1.1 mM EGTA, 10 mM HEPES, and 2 mM Na 2 ATP (pH 7.2). During recordings, cells were superfused with extracellular physiological solution containing 140 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 10 mM glucose (pH 7.4). Designated concentrations of CCh were dissolved in HEPES-buffered solution and applied locally through a thin polyethylene tube positioned near recording cells as previously described (16, 17, 20, 22) . Designated concentrations of antagonists were applied in the perfusion solution. Data were recorded on a computer through a Digidata 1322A A / D converter using p-Clamp 9.2 software (Axon Instruments). The trace was processed for presentation using Origin 6.1 (Origin Lab Corporation, Northampton, MA, USA). Spontaneous EPSCs (sEPSCs) and spontaneous IPSCs (sIPSCs) were recorded in orexin neurons under wholecell voltage-clamp mode at a holding potential of −60 mV in the absence of TTX. sEPSCs were recorded using KCl-based pipette solution containing the sodium channel blocker QX-314 (5 mM) and in the presence of picrotoxin (100 µM) in the perfusion solution. sIPSCs were recorded using KCl-based pipette solution containing QX-314 in the presence of AP-5 (50 µM) and CNQX (20 µM) in the perfusion solution. The frequency and amplitude of sEPSCs and sIPSCs were analyzed using mini analysis software (Synaptosoft, Fort Lee, NJ, USA).
Immunohistochemical study
Sections were prepared from mouse brains as previously described (20, 23) . We used an anti-choline acetyl transferase (ChAT) goat polyclonal antibody (diluted 1:100) (16) and an anti-orexin rabbit antibody (diluted 1:1000) (2). Double staining was accomplished by carrying out the first reaction using biotinylated antigoat horse antibody (Vector Labs, Burlingame, CA, USA) with diamino-benzidine substrate (DAB) in the presence of nickel ammonium sulphate to give a black precipitate (ChAT-ir), followed by second incubation with anti-rabbit goat antibody (Vector), then ABC complex, and finally DAB in the absence of nickel ammonium sulphate to give a brown stain (orexin-ir).
Drugs
Tetrodotoxin (TTX) was purchased from Wako (Osaka). CCh, atropine, pirenzepine, picrotoxin, 4diphenylacetoxy-N-methyl-piperidine methiodide (4-DAMP), N-(2,6-dimethylphenylcarbamoylmethyl) triethylammonium bromide (QX-314), DL-2-amino-5phosphono-pentanoic acid (AP-5), and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) were purchased from Sigma (St. Louis, MO, USA).
Statistical analyses
Data were analyzed by two-way ANOVA followed by post-hoc analysis of significance with Fisher's protected least significant difference test using the Stat View 5.0 software package (Abacus Concepts, Berkeley, CA, USA). Probability (P) values <0.05 were considered statistically significant.
Results
CCh activates 20% of orexin neurons
To examine whether cholinergic agonists affect the activity of orexin neurons, a cholinergic agonist, carbachol (CCh), was applied to orexin neurons. Experiments were performed by means of whole-cell patch clamp using the voltage clamp mode (membrane potential was held at −60 mV). Local application of CCh depolarized the membrane potential of orexin neurons in the presence of TTX ( Fig. 1A) . CCh evoked an inward current in 20% (42 / 215) of orexin neurons and induced an outward current in 1% (2 / 215) of orexin neurons examined. CCh induced an inward current in 20% of orexin neurons in a concentration-dependent manner (Fig. 1B ); E max was 24.3 ± 1.5 pA at 1 mM, and EC 50 was 141.5 ± 18.0 µM (n = 11). These observations suggest that cholinergic agonists excite almost 20% of orexin neurons and inhibit a very small population of orexin neurons in mice.
ChAT-ir axon terminals in apposition to orexin neurons in LHA
To determine whether orexin neurons receive cholinergic input, coronal sections through the region containing orexin neurons were studied using doublelabeled immunostaining for orexin and ChAT. We found that ChAT-immunoreactive nerve endings (black) were observed in the LHA (Fig. 1C ). These nerve endings were observed around the somata and dendrites of orexin-immunoreactive neurons (brown) and made close contacts. Arrows in Fig. 1C show ChAT-immunoreactive nerve endings closely apposed to orexinimmunoreactive cell bodies.
Activation of muscarinic M 3 receptor is involved in CChinduced depolarization
In order to identify the subtype of acetylcholine receptor involved in the CCh-induced depolarization of orexin neurons, we examined the effect of the muscarinic receptor antagonists atropine, 4-DAMP and pirenzepine. The effect of CCh (100 µM) was dosedependently inhibited by the muscarinic receptor antagonist atropine (IC 50 = 0.77 ± 0.22 nM) (Fig. 2B) . The response was inhibited 90% by atropine (10 nM), suggesting that the effect was almost totally mediated by muscarinic receptors, and not by nicotinic receptors. An M 3 antagonist, 4-DAMP, also blocked (IC 50 = 0.30 ± 0.15 nM) the response of CCh (100 µM) with an IC 50 of 0.30 ± 0.15 nM (Fig. 2: A and B) . A high dose of pirenzepine (M 1 antagonist) also blocked the CCh (100 µM) response with significantly lower potency (IC 50 = 59.9 ± 18.6 nM) (Fig. 2B) . The dose-inhibition relationships indicated that the sequence of potency of the antagonists was atropine ≈ 4-DAMP >> pirenzepine. These inhibitions were fully reversible upon washout of antagonists (data not shown). These observations suggest that the CCh-induced response in orexin neurons is mediated by the M 3 muscarinic receptor (24, 25) . These antagonists alone did not show any effects on the membrane potentials of the cells (data not shown).
Activation of NSCC is involved in CCh-induced inward current
According to our previous report, the reversal potential of the CCh-induced inward current was −11.0 ± 2.5 mV (16) . This suggests that CCh activates nonselective cation channels such as transient receptor potential (TRP) channels. To further examine whether nonselective cation channels are involved in the CCh-induced response, we examined the effect of a nonselective cation channel blocker, SKF96365 (26) . SKF96365 inhibited the CCh-induced inward current in orexin neurons in a concentration-dependent manner (Fig. 3) . The CCh-induced inward current was significantly inhibited to 56.7 ± 3.7% (3 µM SKF96365) and 40.3 ± 4.3% (30 µM SKF95365) of the control. An L-type voltage-dependent Ca 2+ -channel blocker, nifedipine, did not affect the response (data not shown). These results suggest that activation of nonselective cation channels is at least partly involved in the CCh-induced activation of orexin neurons. SKF96365 at 30 µM was reported to almost completely inhibit Ca 2+ entry in platelets through NSCC (26) . Therefore, activation of other channels might also be involved in the CCh-induced inward current in orexin neurons, downstream of the The cells were voltage clamped at −60 mV in a whole-cell configuration. The muscarinic antagonists were applied in the perfused solution, whereas CCh was applied locally through a fine polyethylene tube located near the recording neurons. Responses were normalized to the peak current induced by 100 µM CCh, which was applied before each experiment. Values are shown as the mean ± S.E.M. Fig. 3 . Activation of nonselective cation channels is involved in CCh-induced inward current. A and B: CCh-induced inward current was inhibited by the nonselective cation channel blocker, SKF96365, in a concentration-dependent manner (n = 6). SKF96365 (3 and 30 µM) was applied in the perfused solution. B: Graph summarizing the data in A. Responses were normalized to the peak current induced by 100 µM, which was applied before each experiment. Values are shown as the mean ± S.E.M. *, P<0.05. M 3 muscarinic receptor.
Effect of CCh on sEPSC and sIPSC in orexin neurons
To examine the possibility that CCh affects synaptic input to orexin neurons and indirectly modulates the activity of orexin neurons, sEPSC and sIPSC were recorded in orexin neurons under whole-cell voltageclamp mode at a holding potential of −60 mV. CCh (100 µM) had little effect on sEPSC or sIPSC frequency ( Fig. 4 ) or amplitude (data not shown). Similar results were obtained from both CCh-responsive orexin neurons ( Fig. 4A) and CCh-nonresponsive orexin neurons (Fig. 4B) . These observations suggest that CCh does not modulate IPSC or EPSC frequency in orexin neurons.
Discussion
In this study, we applied CCh, a muscarinic receptor agonist, to a large number of orexin neurons and revealed that CCh activated almost 20% of orexin neurons and inhibited a very small population of orexin neurons (1%) by using an in vitro slice patch clamp method. We found that CCh induced an inward current in orexin neurons. Pharmacological studies suggested that M 3 muscarinic receptors and NSCCs are involved in the response. CCh induces inward currents in orexin neurons with an EC 50 value of 141.5 ± 18.0 µM (n = 11).
This value was higher than those for M 3 receptors in previous reports (27, 28) . This difference might stem from the differences in the experimental systems; because we applied CCh by local application using a thin tube located near recording cells, the actual concentrations on the cells might be lower than the designated concentrations due to the diffusion. Alternatively, the existence of spare receptors might explain the lower potency.
Acetylcholine is a neurotransmitter that is known to have an important role in regulating vigilance state. Cholinergic neurons are localized in the basal forebrain and brainstem. The discharge rates of cholinergic neurons in the brain stem show two types: some neurons are implicated in the maintenance of wakefulness and other neurons in regulation of REM sleep and muscle atonia during REM sleep (29) . In cholinergic neurons of BF, the discharge rate is higher during active waking than in quiet waking (11) . Orexin neurons also show higher activity during active waking (30) . Orexins activate basal forebrain cholinergic neurons via the OX 2 receptor (14) . There might be reciprocal circuits between orexin neurons and cholinergic neurons in the basal forebrain.
Cholinergic neurons in the BF have been shown to provide synaptic input to orexin neurons (16, 31) . In the present study, we found that orexin neurons were in Fig. 4 . CCh had no effect on glutamatergic or GABAergic synaptic transmission to orexin neurons. sEPSCs and sIPSCs were recorded by whole-cell voltage clamp at a holding potential of −60 mV. sEPSCs were recorded in the presence of the GABAA-receptor antagonist picrotoxin (100 µM), whereas sIPSCs were recorded in the presence of the ionotropic glutamate receptor antagonists AP-5 (50 µM) and CNQX (20 µM). apposition to ChAT-ir neurons (Fig. 1C ). We also found that CCh activated almost 20% of orexin neurons through the M 3 muscarinic receptor. It is reported that the M 3 type muscarinic receptor couples to the G q/ 11 class of G proteins and often couples to non-selective cation channels (32) . M 3 muscarinic receptor is widely expressed throughout the central nervous system including the diencephalon (33) . Mice deficient in the M 3 muscarinic receptor gene display significant decreases in food intake, body weight, and peripheral fat deposits and significant elevations of oxygen consumption and locomotor activity (34, 35) . These studies demonstrate that the M 3 muscarinic receptor might play a role in maintaining the level of energy expenditure. In sleep/ wakefulness regulation, daily REM sleep amount was significantly decreased in mice lacking the M 3 receptor gene (36) , supporting the idea that cholinergic neurons play important roles in regulation and maintenance of REM sleep. Our present work suggests that cholinergic neurons modulate the vigilance state through M 3 receptors on orexin neurons. However, because M 3 muscarinic receptors are widely distributed throughout the brain, the results of genetic studies on the M 3 muscarinic receptor reflect the consequent lack of M 3 receptor in regions of the whole brain. Therefore, it will be necessary to examine mice with selective deletion of the M 3 muscarinic receptor gene in orexin neurons to reveal the precise role of the M 3 muscarinic receptor in orexin neurons.
In conclusion, we revealed the effect of the cholinergic agonist CCh on orexin neurons. An inward current via activation of the M 3 muscarinic receptor and nonselective cation channels was induced in about 20% of the orexin neurons, and an outward current was induced in a small number of orexin neurons. Cholinergic neurons might contribute to maintenance of the waking state and REM sleep in animals at least partly through modulating orexin neurons.
